Today's Portrait Highlights

Bone Index Finland Ltd

Bone Index is one of the most promising Life Science Company in Scandinavia 2014 (Nordic Star Award) and one of Europe’s top new manufacturers of medical devices 2015 (Healthtech Summit). The mission is to reduce the number of osteoporotic fractures by one million globally per year and thus increase the quality of life of families. The aim is bring the diagnostics from special healthcare to primary healthcare with Bindex® point-of-care technology.

Garage48

People are often afraid to start their own project or business. Common problems include lack of know-how and co-founders, lack of money, unknown risks etc. Garage48 is here to change that mindset and show that it's all about positive "let's do it" attitude, creative team members and a motivating deadline. Less talk, more action! Garage48 event series started in Estonia in April 2010 and have expanded to other countries in Northern Europe and Africa since then. All Garage48 events are held in English and have ~100 international participants. Participants have different skills, ranging from software development to design, marketing, sales and entrepreneurship. Garage48 events usually start at 5pm on a Friday evening. All participants gather together in a big room and pitch about 30 to 40 ideas on stage. Each idea is put on the wall and everyone can choose their favourite idea and team. Usually about 12-15 ideas will be selected and teams start working.

QPS

Founded in 1995, QPS is a GLP/GCP-compliant contract research organization (CRO) supporting discovery, preclinical and clinical drug development. We provide quality services to pharmaceutical and biotechnology clients Worldwide. QPS is well known as a leading CRO for CNS drug development. The availability of the most predictive disease models and unparalleled experience with studies performed for biopharmaceutical companies of all sizes turn QPS into the first choice for most research needs. Validated transgenic and non-transgenic in vitro and in vivo models cover most targets of AD, PD, HD and other neurodegenerative diseases.